A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Public ClinicalTrials.gov record NCT05038020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).
Study identification
- NCT ID
- NCT05038020
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2021 (Actual)
- Primary completion
- Dec 9, 2021 (Actual)
- Completion
- Apr 19, 2022 (Actual)
- Last update posted
- Nov 1, 2023
2021 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 132 | Phoenix | Arizona | 85021 | — |
| Site 136 | Phoenix | Arizona | 85053 | — |
| Site 123 | Glendale | California | 91203 | — |
| Site 121 | Huntington Beach | California | 92647 | — |
| Site 116 | Clearwater | Florida | 33761 | — |
| Site 117 | Sarasota | Florida | 34239 | — |
| Site 118 | Winter Haven | Florida | 33880 | — |
| Site 120 | Oak Forest | Illinois | 60452 | — |
| Site 133 | Beaufort | South Carolina | 29902 | — |
| Site 127 | Ladson | South Carolina | 29456 | — |
| Site 122 | Arlington | Texas | 76012 | — |
| Site 130 | Bellaire | Texas | 77401 | — |
| Site 126 | Harlingen | Texas | 78550 | — |
| Site 134 | Houston | Texas | 77025 | — |
| Site 129 | Katy | Texas | 77494 | — |
| Site 128 | San Antonio | Texas | 78240 | — |
| Site 125 | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05038020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05038020 live on ClinicalTrials.gov.